← Leaderboards
Evan Charles Unger
Imarx Therapeutics, Inc.
$4,851,251
Attributed
$9,643,547
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,643,547 · 13
By mechanism
R44$6,534,084 · 4
R41$1,317,820 · 4
U44$900,552 · 1
R43$666,091 · 3
N43$225,000 · 1
Top collaborators
- Baldassarre Stea3 shared
- Michael Farris Waters3 shared
- Sanjiv S Gambhir2 shared
- John Martin Brown1 shared
- Jeremy Dahl1 shared
- Katherine Havranek1 shared
- Shelby Kutty1 shared
- Helena Willington Morrison1 shared
Others in their field
Top investigators on “Animals”
- David Heimbrook · Leidos Biomedical Research, Inc.$534,904,829
- Richard Webby · St. Jude Children'S Research Hospital$259,408,394
- Eric S Lander · Whitehead Institute For Biomedical Res$209,574,154
- Dennis R. Burton · Scripps Research Institute$204,129,233
- Richard K. Wilson · Washington University$130,501,539
- Mark S Klempner · Tufts Medical Center$129,182,794
Research focus
AnimalsDoseContrast MediaOperative Surgical ProceduresOxygenMagnetic Resonance ImagingPharmaceutical PreparationsEmulsionsUltrasonographyPerfluoropentaneDiagnosisHourRandomizedClinical TrialsTumorAffectStandard Of CarePlacebosAgedAftercareBasePhase Ii TrialHypoxiaIn Vitro
Grant awards (19)
Liquid Biopsy in Glioblastoma Treated with Chemoradiation and an Oxygen Therapeutic$919,366
R44 · FY2025 · CA · contact PI
Dodecafluoropentane emulsion (DDFPe), NanO2⢠as Cerebroprotectant in Ischemic Stroke$299,943
U44 · FY2025 · NS · contact PI
Dodecafluoropentane emulsion (DDFPe), NanO2⢠as Cerebroprotectant in Ischemic Stroke$299,243
U44 · FY2024 · NS · contact PI
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$492,571
R44 · FY2023 · CA · contact PI
Dodecafluoropentane emulsion (DDFPe), NanO2⢠as Cerebroprotectant in Ischemic Stroke$301,366
U44 · FY2023 · NS · contact PI
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$1,000,000
R44 · FY2022 · CA · contact PI
NanO2 as a Cerebroprotectant in a tMCAO Stroke Model in Mice$478,050
R41 · FY2021 · NS · contact PI
Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development$1,033,173
R44 · FY2019 · CA · contact PI
Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development$963,578
R44 · FY2018 · CA · contact PI
Development of a syringe/sonication device employed to administer DDFPe in the prehospital setting$143,988
R43 · FY2018 · NS · contact PI
Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma$1,000,000
R44 · FY2017 · CA · contact PI
Dodecafluoropentane Prevents Ischemia Reperfusion Injury in Contemporary Acute Myocardial Infarction Management$317,743
R43 · FY2017 · HL · contact PI
B7-H3-Targeted Contrast Agent for Ultrasonic Imaging of Breast Cancer$298,820
R41 · FY2016 · CA · contact PI
Pancreatic Ductal Adenocarcinoma Targeted Ultrasound Contrast Agent Development$297,786
R41 · FY2016 · CA · contact PI
Targeted and Non-targeted Microbubbles for Pediatric Applications$243,164
R41 · FY2016 · HD · contact PI
Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma$1,000,000
R44 · FY2014 · CA · contact PI
IGF::OT::IGF SBIR TOPIC 85 TO SUPPORT THE DEVELOPMENT OF TARGET SPECIFIC MOLECULAR IMAGING AGENTS IN COMBINATION WITH EXISTING IMAGING MODALITIES TO DETECT HIGH RISK ATHEROSCLEROTIC PLAQUE.$225,000
N43 · FY2014 · HL · contact PI
Development of Novel Sensitizer to Improve Response of Hypoxic Tumors to Radiatio$204,360
R43 · FY2010 · CA · contact PI
Sonothrombolysis of Vascular Clots with Targeted Bubbles$125,396
R44 · FY2007 · HL · contact PI